Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma

被引:11
|
作者
Miyazaki, Katsuki [1 ,2 ]
Morine, Yuji [2 ]
Xu, Caiming [1 ]
Nakasu, Chiharu [2 ]
Wada, Yuma [2 ]
Teraoku, Hiroki [2 ]
Yamada, Shinichiro [2 ]
Saito, Yu [2 ]
Ikemoto, Tetsuya [2 ]
Shimada, Mitsuo [2 ]
Goel, Ajay [1 ]
机构
[1] City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Mol Diagnost & Expt Therapeut, Duarte, CA 91010 USA
[2] Tokushima Univ, Dept Surg, Tokushima 7791510, Japan
关键词
Lenvatinib; Curcumin; EGFR; hepatocellular carcinoma; PI3K-AKT; resistance; ATEZOLIZUMAB PLUS BEVACIZUMAB; 1ST-LINE TREATMENT; NON-INFERIORITY; SORAFENIB; EFFICACY; CANCER; SAFETY;
D O I
10.3390/cells12040612
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits its clinical significance for treating patients with HCC. Recent evidence suggests that epidermal growth factor receptor (EGFR) activation can trigger Lenvatinib-resistance; and is considered an important therapeutic target in HCC. Curcumin, one of the most studied naturally occurring botanicals with robust anti-cancer activity, is also reported to be a potent tyrosine kinase inhibitor. In this study, we hypothesized that the anti-EGFR potential of Curcumin might help overcome Lenvatinib resistance in HCC. We established two Lenvatinib-resistant cells and discovered that a combination of Curcumin and Lenvatinib exhibited a synergistic anti-tumor efficacy in the resistant HCC cell lines. In line with previous reports, Lenvatinib-resistant cell lines revealed significant activation of the EGFR, and genomewide transcriptomic profiling analysis identified that the PI3K-AKT pathway was associated with Lenvatinib resistance. The combination treatment with Curcumin and Lenvatinib dramatically suppressed gene and protein expression of the EGFR-PI3K-AKT pathway, suggesting Curcumin overcomes Lenvatinib resistance via inhibition of EGFR. We further validated these findings in tumor spheroids derived from resistant cell lines. In conclusion, we, for the first time, report that Curcumin reverses Lenvatinib resistance in HCC, and that their combination has clinical application potential for adjunctive treatment in HCC.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] MD2 blockage prevents the migration and invasion of hepatocellular carcinoma cells via inhibition of the EGFR signaling pathway
    Qi, Yajun
    Fang, Qilu
    Li, Qinglin
    Ding, Haiying
    Shu, Qi
    Hu, Yan
    Xin, Wenxiu
    Fang, Luo
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (04) : 1873 - 1883
  • [22] Curcumin suppresses MUC5AC production via interfering with the EGFR signaling pathway
    Tang, Lingling
    Chen, Qingge
    Sun, Li
    Zhu, Linyun
    Liu, Jinjin
    Meng, Ziyu
    Ni, Zhenhua
    Wang, Xiongbiao
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 42 (01) : 497 - 504
  • [23] Hepatocellular Carcinoma: IGF/FGF Signaling Pathway contributes to Sorafenib Resistance
    Weiss, Johannes
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2017, 55 (07):
  • [24] Upregulation of Extrinsic Apoptotic Pathway in Curcumin-Mediated Antiproliferative Effect on Human Pancreatic Carcinogenesis
    Youns, Mahmoud
    Fathy, Gihan Mahmoud
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2013, 114 (12) : 2654 - 2665
  • [25] Hedgehog signaling pathway mediates invasion and metastasis of hepatocellular carcinoma via ERK pathway
    Jing-tao Lu
    Wen-di Zhao
    Wei He
    Wei Wei
    Acta Pharmacologica Sinica, 2012, 33 : 691 - 700
  • [26] Hedgehog signaling pathway mediates invasion and metastasis of hepatocellular carcinoma via ERK pathway
    Lu, Jing-tao
    Zhao, Wen-di
    He, Wei
    Wei, Wei
    ACTA PHARMACOLOGICA SINICA, 2012, 33 (05) : 691 - 700
  • [27] Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
    Tao, Meng
    Han, Jing
    Shi, Juanyi
    Liao, Hao
    Wen, Kai
    Wang, Weidong
    Mui, Sintim
    Li, Huoming
    Yan, Yongcong
    Xiao, Zhiyu
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1069 - 1083
  • [28] Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
    Qin, Yongqing
    Han, Shisong
    Yu, Yahan
    Qi, Ding
    Ran, Mengnan
    Yang, Mingqi
    Liu, Yanyan
    Li, Yunyi
    Lu, Ligong
    Liu, Yu
    Li, Yong
    LIVER INTERNATIONAL, 2024, 44 (08) : 1808 - 1831
  • [29] MICRORNA-1297 IS INVOLVED IN THE RESISTANCE OF LENVATINIB IN HEPATOCELLULAR CARCINOMA
    Kogure, Takayuki
    Satoh, Mari
    Ito, Takehito
    Satoh, Kennichi
    HEPATOLOGY, 2023, 78 : S1944 - S1945
  • [30] Curcumin-mediated suppression of AKT activity induces apoptosis in papillary thyroid carcinoma cells
    Al-Thari, Sara
    Khan, Asma
    Hussain, Azhar
    Ahmed, Maqbool
    Al-Kuraya, Khawla
    Uddin, Shahab
    CANCER RESEARCH, 2009, 69